Spotlight
Urology Times Journal
Prostate Cancer
Bladder Cancer
OAB and Incontinence
SUO Annual Meeting
Around the Practice: January 2021 Virtual Tumor Board
AUA Conference
Evolving Treatment Approaches
Perspectives in mCRPC
The Latest in Testosterone Replacement Therapy
Opinion
Blogs
Residents Lounge
Business
Health IT
Health Law & Policy
Malpractice Consult
Personal Finance
Practice Management
News
Clinical
All Clinical
Benign Conditions
Benign Prostatic Hyperplasia
Bladder Cancer
Challenging Anatomy
Drug Therapy
Female Urology
Genitourinary Cancers
Kidney Cancer
Kidney Stones
Men's Health
Pediatrics
Prostate Cancer
Sexual Dysfunction
Urologic Surgery
Media
Podcasts
'Y'tube
K-Cast
UTv Videos
Around the Practice
BPH Videos
Medical World News
Readout 360
Viewpoints
Conferences
Publications
Urologists in Cancer Care
Urology Times Journal
Events
Live Events
Virtual Events
Resources
Education
Interactive Tools
Job Board
Sponsored Resources
Subscribe
eNewsletter
Print Subscription
Search
Spotlight
Urology Times Journal
Prostate Cancer
Bladder Cancer
OAB and Incontinence
SUO Annual Meeting
Around the Practice: January 2021 Virtual Tumor Board
AUA Conference
Evolving Treatment Approaches
Perspectives in mCRPC
The Latest in Testosterone Replacement Therapy
Opinion
Blogs
Residents Lounge
Business
See All >
Health IT
Health Law & Policy
Malpractice Consult
Personal Finance
Practice Management
Alpha-blocker, PDE-5 combo doesn't lead to CV events
July 1, 2004
Alpha-blocker, PDE-5 combo doesn't lead to CV events
Related Content:
Drug Therapy
|
News
Related Article >>>
